A Phase I Trial of Incorporating Natural Killer (K-NK) cells for Patients with Chronic Myeloid Leukemia (CML) and Molecular Residual Disease After Tyrosine Kinase Inhibitor (TKI) Therapy
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Kiadis Pharma
Start Date
March 3, 2021
End Date
March 14, 2026
Administered By
Duke Cancer Institute
Awarded By
Kiadis Pharma
Start Date
March 3, 2021
End Date
March 14, 2026